

Pontus Eriksson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8768934/publications.pdf>

Version: 2024-02-01

38
papers

5,660
citations

361045

20
h-index

315357

38
g-index

39
all docs

39
docs citations

39
times ranked

8512
citing authors

#	ARTICLE	IF	CITATIONS
1	TGF β 2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <i>Nature</i> , 2018, 554, 544-548.	13.7	3,359
2	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.	0.9	741
3	Molecular classification of urothelial carcinoma: global <scp>mRNA</scp> classification versus tumourâ€cell phenotype classification. <i>Journal of Pathology</i> , 2017, 242, 113-125.	2.1	258
4	Toward a Molecular Pathologic Classification of Urothelial Carcinoma. <i>American Journal of Pathology</i> , 2013, 183, 681-691.	1.9	155
5	A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. <i>Scientific Reports</i> , 2018, 8, 3737.	1.6	128
6	Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. <i>Nature Medicine</i> , 2018, 24, 463-473.	15.2	120
7	A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma. <i>European Urology</i> , 2015, 68, 824-832.	0.9	111
8	Biological determinants of bladder cancer gene expression subtypes. <i>Scientific Reports</i> , 2015, 5, 10957.	1.6	102
9	Cell-Type-Specific Gene Programs of the Normal Human Nephron Define Kidney Cancer Subtypes. <i>Cell Reports</i> , 2017, 20, 1476-1489.	2.9	75
10	Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. <i>European Urology</i> , 2022, 81, 523-532.	0.9	65
11	Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems. <i>BMC Medical Genomics</i> , 2015, 8, 25.	0.7	58
12	Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. <i>International Journal of Cancer</i> , 2020, 146, 2636-2647.	2.3	56
13	On Molecular Classification of Bladder Cancer: Out of One, Many. <i>European Urology</i> , 2015, 68, 921-923.	0.9	47
14	Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases. <i>Modern Pathology</i> , 2018, 31, 1869-1881.	2.9	47
15	Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma. <i>Genome Medicine</i> , 2015, 7, 23.	3.6	42
16	HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts. <i>Oncotarget</i> , 2017, 8, 48905-48914.	0.8	35
17	<i>FGFR3</i> mutation increases bladder tumourigenesis by suppressing acute inflammation. <i>Journal of Pathology</i> , 2018, 246, 331-343.	2.1	33
18	Molecular pathology of the luminal class of urothelial tumors. <i>Journal of Pathology</i> , 2019, 249, 308-318.	2.1	30

#	ARTICLE	IF	CITATIONS
19	Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 791-799.	0.8	30
20	Molecular subtype classification of urothelial carcinoma in Lynch syndrome. <i>Molecular Oncology</i> , 2018, 12, 1286-1295.	2.1	25
21	Novel genetic loci associated with long-term deterioration in blood lipid concentrations and coronary artery disease in European adults. <i>International Journal of Epidemiology</i> , 2016, 46, dyw245.	0.9	17
22	A comparison of rule-based and centroid single-sample multiclass predictors for transcriptomic classification. <i>Bioinformatics</i> , 2022, 38, 1022-1029.	1.8	17
23	Patient-Derived Bladder Cancer Organoid Models in Tumor Biology and Drug Testing: A Systematic Review. <i>Cancers</i> , 2022, 14, 2062.	1.7	14
24	Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight. <i>Cell Reports Medicine</i> , 2021, 2, 100472.	3.3	13
25	The Lund Molecular Taxonomy Applied to Non-Muscle-Invasive Urothelial Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 992-1008.	1.2	13
26	Promoter-associated proteins of EPAS1 identified by enChIP-MS: A putative role of HDX as a negative regulator. <i>Biochemical and Biophysical Research Communications</i> , 2018, 499, 291-298.	1.0	10
27	Detailed Analysis of Focal Chromosome Arm 1q and 6p Amplifications in Urothelial Carcinoma Reveals Complex Genomic Events on 1q, and SOX4 as a Possible Auxiliary Target on 6p. <i>PLoS ONE</i> , 2013, 8, e67222.	1.1	10
28	Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 1692.	1.7	8
29	multiclassPairs: an R package to train multiclass pair-based classifier. <i>Bioinformatics</i> , 2021, 37, 3043-3044.	1.8	7
30	Re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. <i>Eur Urol</i> 2019;75:423-32. <i>European Urology</i> , 2019, 75, e106-e107.	0.9	6
31	Molecular pathology of the non-luminal Ba/Sq-like and Sc/NE-like classes of urothelial tumours: an integrated immunohistochemical analysis. <i>Human Pathology</i> , 2022, , .	1.1	6
32	Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. <i>J Clin Oncol</i> 2017;35:48-55. <i>European Urology</i> , 2017, 72, e135-e136.	0.9	5
33	Recurring urothelial carcinomas show genomic rearrangements incompatible with a direct relationship. <i>Scientific Reports</i> , 2020, 10, 19539.	1.6	4
34	When the Molecular Subtype Is Hidden Behind a Veil of Stroma. <i>European Urology</i> , 2021, 80, 160-161.	0.9	4
35	Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? <i>Ther Adv Med Oncol</i> 2018;10:1758835918788310. <i>European Urology</i> , 2019, 75, e37-e38.	0.9	3
36	Re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. <i>Eur Urol</i> ;2020:533-7. <i>European Urology</i> , 2020, 78, e228-e229.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. <i>Eur Urol</i> 2020;77:434-438. <i>European Urology</i> , 2020, 77, 436-438.	0.9	1
38	Reply to Joep J. de Jong and Ewan A. Gibba's Letter to the Editor re: Gottfrid Sjöndahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2021.10.035 . Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?. <i>European Urology</i> , 2022, 81, e92-e92.	0.9	0